当前位置： SCI文献检索 > Alzheimers Research & Therapy期刊下所有文献 > Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey.

Use of mild cognitive impairment and prodromal AD/MCI due to AD in clinical care: a European survey.

Abstract：

INTRODUCTION:The diagnosis of mild cognitive impairment (MCI) refers to cognitive impairment not meeting dementia criteria. A survey among members of the American Association of Neurology (AAN) showed that MCI was considered a useful diagnosis. Recently, research criteria have been proposed for the diagnosis of Alzheimer's disease (AD) in MCI based on AD biomarkers (prodromal AD/MCI due to AD). The aim of this study was to investigate the attitudes of clinicians in Europe on the clinical utility of MCI and prodromal AD/MCI due to AD criteria. We also investigated whether the prodromal AD/MCI due to AD criteria impacted management of MCI patients. METHODS:An online survey was performed in 2015 among 102 members of the European Academy of Neurology (EAN) and the European Alzheimer's Disease Consortium (EADC). Questions were asked on how often criteria were used, how they were operationalized, how they changed patient management, and what were considered advantages and limitations of MCI and prodromal AD/MCI due to AD. The questionnaire consisted of 47 questions scored on a Likert scale. RESULTS:Almost all respondents (92%) used the MCI diagnosis in clinical practice. Over 80% of the EAN/EADC respondents found a MCI diagnosis useful because it helped to label the cognitive problem, involve patients in planning for the future, and start risk reduction activities. These findings were similar to those reported in the AAN survey. Research criteria for prodromal AD/MCI due to AD were used by 68% of the EAN/EADC respondents. The most common reasons to use the criteria were increased certainty of diagnosis (86%), increased possibilities to provide counseling (51%), facilitation of follow-up planning (48%), start of medical intervention (49%), and response to patients' wish for a diagnosis (41%). Over 70% of the physicians considered that a diagnosis of prodromal AD/MCI due to AD had an added value over the MCI diagnosis. CONCLUSIONS:The diagnostic criteria of MCI and prodromal AD/MCI due to AD are commonly used among EAN/EADC members. The prodromal AD/MCI due to AD were considered clinically useful and impacted patient management and communication.

journal_name

Alzheimers Res Ther

journal_title

Alzheimer's research & therapy

authors

Bertens D,Vos S,Kehoe P,Wolf H,Nobili F,Mendonça A,van Rossum I,Hort J,Molinuevo JL,Heneka M,Petersen R,Scheltens P,Visser PJ

doi

10.1186/s13195-019-0525-9

subject

Has Abstract

pub_date

2019-08-22 00:00:00

pages

74

issue

1

issn

1758-9193

pii

10.1186/s13195-019-0525-9

journal_volume

11

pub_type

杂志文章

相关文献

Alzheimers Research & Therapy文献大全
  • The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.

    abstract：INTRODUCTION:Depression and psychosis are two of the most severe neuropsychiatric symptoms (NPS) in dementia with Lewy bodies (DLB) and Alzheimer's disease (AD). Both NPS have negative effects on cognitive performance and life expectancy. The current study aimed to investigate and compare monoaminergic etiologies betwe...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-014-0090-1

    authors： Vermeiren Y,Van Dam D,Aerts T,Engelborghs S,Martin JJ,De Deyn PP

    更新日期：2015-02-11 00:00:00

  • Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER).

    abstract：BACKGROUND:The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was a multicenter randomized controlled trial that reported beneficial effects on cognition for a 2-year multimodal intervention (diet, exercise, cognitive training, vascular risk monitoring) versus control (gene...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1186/s13195-019-0506-z

    authors： Stephen R,Liu Y,Ngandu T,Antikainen R,Hulkkonen J,Koikkalainen J,Kemppainen N,Lötjönen J,Levälahti E,Parkkola R,Pippola P,Rinne J,Strandberg T,Tuomilehto J,Vanninen R,Kivipelto M,Soininen H,Solomon A,FINGER study grou

    更新日期：2019-06-04 00:00:00

  • Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease.

    abstract：BACKGROUND:Down syndrome (DS), caused by chromosome 21 trisomy, is associated with an ultra-high risk of dementia due to Alzheimer's disease (AD), driven by amyloid precursor protein (APP) gene triplication. Understanding relevant molecular differences between those with DS, those with sporadic AD (sAD) without DS, and...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0477-0

    authors： Startin CM,Ashton NJ,Hamburg S,Hithersay R,Wiseman FK,Mok KY,Hardy J,Lleó A,Lovestone S,Parnetti L,Zetterberg H,Hye A,LonDownS Consortium.,Strydom A

    更新日期：2019-03-21 00:00:00

  • Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.

    abstract：BACKGROUND:Disclosure of amyloid positron emission tomography (PET) results to individuals without dementia has become standard practice in secondary prevention trials and also increasingly occurs in clinical practice. However, this is controversial given the current lack of understanding of the predictive value of a P...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-018-0398-3

    authors： de Wilde A,van Buchem MM,Otten RHJ,Bouwman F,Stephens A,Barkhof F,Scheltens P,van der Flier WM

    更新日期：2018-07-28 00:00:00

  • Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.

    abstract：:In May 2012, the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia brought together in Montreal experts from around Canada to update Canadian recommendations for the diagnosis and management of patients with neurodegenerative conditions associated with deterioration of cognition. Multiple...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt199

    authors： Soucy JP,Bartha R,Bocti C,Borrie M,Burhan AM,Laforce R,Rosa-Neto P

    更新日期：2013-07-08 00:00:00

  • The medical food Souvenaid affects brain phospholipid metabolism in mild Alzheimer's disease: results from a randomized controlled trial.

    abstract：BACKGROUND:Synaptic dysfunction contributes to cognitive impairment in Alzheimer's disease and may be countered by increased intake of nutrients that target brain phospholipid metabolism. In this study, we explored whether the medical food Souvenaid affects brain phospholipid metabolism in patients with Alzheimer's dis...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,随机对照试验

    doi：10.1186/s13195-017-0286-2

    authors： Rijpma A,van der Graaf M,Lansbergen MM,Meulenbroek O,Cetinyurek-Yavuz A,Sijben JW,Heerschap A,Olde Rikkert MGM

    更新日期：2017-07-26 00:00:00

  • Brain metabolism and cerebrospinal fluid biomarkers profile of non-amnestic mild cognitive impairment in comparison to amnestic mild cognitive impairment and normal older subjects.

    abstract：INTRODUCTION:Mild cognitive impairment (MCI) is classically considered a transitional stage between normal aging and dementia. Non-amnestic MCI (naMCI) patients, however, typically demonstrate cognitive deficits other than memory decline. Furthermore, as a group, naMCI have a lower rate of an eventual dementia diagnosi...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-015-0143-0

    authors： Coutinho AM,Porto FH,Duran FL,Prando S,Ono CR,Feitosa EA,Spíndola L,de Oliveira MO,do Vale PH,Gomes HR,Nitrini R,Brucki SM,Buchpiguel CA

    更新日期：2015-09-15 00:00:00

  • Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials.

    abstract：:Lewy body dementia (LBD), including dementia with Lewy bodies and Parkinson's disease dementia, affects over a million people in the USA and has a substantial impact on patients, caregivers, and society. Symptomatic treatments for LBD, which can include cognitive, neuropsychiatric, autonomic, sleep, and motor features...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-020-00703-5

    authors： Goldman JG,Forsberg LK,Boeve BF,Armstrong MJ,Irwin DJ,Ferman TJ,Galasko D,Galvin JE,Kaufer D,Leverenz J,Lippa CF,Marder K,Abler V,Biglan K,Irizarry M,Keller B,Munsie L,Nakagawa M,Taylor A,Graham T

    更新日期：2020-10-29 00:00:00

  • Retinal microvasculature dysfunction is associated with Alzheimer's disease and mild cognitive impairment.

    abstract：BACKGROUND:The retina and brain share many neuronal and vasculature characteristics. We investigated the retinal microvasculature in Alzheimer's disease (AD) and mild cognitive impairment (MCI) using optical coherence tomography angiography (OCTA). METHODS:In this cross-sectional study, 24 AD participants, 37 MCI part...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00724-0

    authors： Chua J,Hu Q,Ke M,Tan B,Hong J,Yao X,Hilal S,Venketasubramanian N,Garhöfer G,Cheung CY,Wong TY,Chen CL,Schmetterer L

    更新日期：2020-12-04 00:00:00

  • The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease.

    abstract：BACKGROUND:Synapse damage and loss are fundamental to the pathophysiology of Alzheimer's disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical development approaches for AD therapeutics that can demonstrate reduction of synapse damage or loss. ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-020-00588-4

    authors： Colom-Cadena M,Spires-Jones T,Zetterberg H,Blennow K,Caggiano A,DeKosky ST,Fillit H,Harrison JE,Schneider LS,Scheltens P,de Haan W,Grundman M,van Dyck CH,Izzo NJ,Catalano SM,Synaptic Health Endpoints Working Group.

    更新日期：2020-03-02 00:00:00

  • Cognitive composite score association with Alzheimer's disease plaque and tangle pathology.

    abstract：BACKGROUND:Cognitive composite scores are used as the primary outcome measures for Alzheimer's disease (AD) prevention trials; however, the extent to which these composite measures correlate with AD pathology has not been fully investigated. Since many on-going AD prevention studies are testing therapies that target ei...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-018-0401-z

    authors： Malek-Ahmadi M,Chen K,Perez SE,He A,Mufson EJ

    更新日期：2018-09-11 00:00:00

  • Testing whether the progression of Alzheimer's disease changes with the year of publication, additional design, and geographical area: a modeling analysis of literature aggregate data.

    abstract：BACKGROUND:Our objectives were to develop a disease progression model for cognitive decline in Alzheimer's disease (AD) and to determine whether disease progression of AD is related to the year of publication, add-on trial design, and geographical regions. METHODS:Placebo-controlled randomized AD clinical trials were ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00630-5

    authors： Zhang N,Zheng X,Liu H,Zheng Q,Li L

    更新日期：2020-05-26 00:00:00

  • Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers.

    abstract：BACKGROUND:Results from recent clinical studies suggest that cerebrospinal fluid (CSF) biomarkers that are indicative of Alzheimer's disease (AD) can be replicated in blood, e.g. amyloid-beta peptides (Aβ42 and Aβ40) and neurofilament light chain (NFL). Such data proposes that blood is a rich source of potential biomar...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0545-5

    authors： Ashton NJ,Suárez-Calvet M,Heslegrave A,Hye A,Razquin C,Pastor P,Sanchez-Valle R,Molinuevo JL,Visser PJ,Blennow K,Hodges AK,Zetterberg H

    更新日期：2019-11-28 00:00:00

  • Subjective cognitive decline and subsequent dementia: a nationwide cohort study of 579,710 people aged 66 years in South Korea.

    abstract：BACKGROUND:Subjective cognitive decline (SCD) is a potential risk factor for dementia. We aimed to investigate the association between SCD and subsequent dementia in a nationwide population-based cohort in South Korea. METHODS:This cohort included 579,710 66-year-old adults who were followed for a total of 3,870,293 p...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00618-1

    authors： Lee YC,Kang JM,Lee H,Kim K,Kim S,Yu TY,Lee EM,Kim CT,Kim DK,Lewis M,Won HH,Jessen F,Myung W

    更新日期：2020-05-06 00:00:00

  • Active immunotherapy options for Alzheimer's disease.

    abstract：:Alzheimer's disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protein (Aβ) and/or hyperphosphorylated tau protein in the brain. At present, current therapies provide temporary sy...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/alzrt237

    authors： Winblad B,Graf A,Riviere ME,Andreasen N,Ryan JM

    更新日期：2014-01-30 00:00:00

  • Older patients are still under-represented in clinical trials of Alzheimer's disease.

    abstract：BACKGROUND:The age gap between participants in trials and patients who could benefit from the drugs studied has been widely documented across different clinical areas. Patients with dementia included in clinical research are systematically younger than those in the general population. We examined the age gap between pa...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,评审

    doi：10.1186/s13195-016-0201-2

    authors： Banzi R,Camaioni P,Tettamanti M,Bertele' V,Lucca U

    更新日期：2016-08-12 00:00:00

  • Cognitive training and brain stimulation in prodromal Alzheimer's disease (AD-Stim)-study protocol for a double-blind randomized controlled phase IIb (monocenter) trial.

    abstract：BACKGROUND:Given the growing older population worldwide, and the associated increase in age-related diseases, such as Alzheimer's disease (AD), investigating non-invasive methods to ameliorate or even prevent cognitive decline in prodromal AD is highly relevant. Previous studies suggest transcranial direct current stim...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00692-5

    authors： Thams F,Kuzmina A,Backhaus M,Li SC,Grittner U,Antonenko D,Flöel A

    更新日期：2020-11-07 00:00:00

  • Systemic and central nervous system metabolic alterations in Alzheimer's disease.

    abstract：BACKGROUND:Metabolic alterations, related to cerebral glucose metabolism, brain insulin resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer's disease (AD) on both the systemic and central nervous system level. To study the extent and significance of these alterations in AD, quanti...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-019-0551-7

    authors： van der Velpen V,Teav T,Gallart-Ayala H,Mehl F,Konz I,Clark C,Oikonomidi A,Peyratout G,Henry H,Delorenzi M,Ivanisevic J,Popp J

    更新日期：2019-11-28 00:00:00

  • A language-based sum score for the course and therapeutic intervention in primary progressive aphasia.

    abstract：BACKGROUND:With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for the follow-up of patients are needed to describe disease progression and to evaluate potential therapeutic effects. So far, volumetric brain changes have been proposed as clinical endpoints in the lit...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-018-0345-3

    authors： Semler E,Anderl-Straub S,Uttner I,Diehl-Schmid J,Danek A,Einsiedler B,Fassbender K,Fliessbach K,Huppertz HJ,Jahn H,Kornhuber J,Landwehrmeyer B,Lauer M,Muche R,Prudlo J,Schneider A,Schroeter ML,Ludolph AC,Otto M,FTLD

    更新日期：2018-04-25 00:00:00

  • Statins and therapy of Alzheimer's disease: questions of efficacy versus trial design.

    abstract：:Recent trials of statins produced no benefit for subjects with Alzheimer's disease. These negative studies add to a growing list of negative clinical trials. These data point to a need for reevaluating the pathophysiology of late-onset Alzheimer's disease. Late-onset Alzheimer's disease might result from the cumulativ...

    journal_title：Alzheimer's research & therapy

    pub_type： 社论

    doi：10.1186/alzrt101

    authors： Wolozin B

    更新日期：2012-01-16 00:00:00

  • Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40).

    abstract：BACKGROUND:The pathophysiology of neurodegeneration is complex. Its diagnosis requires an early identification of sequential changes in several hallmarks in the brains of affected subjects. The presence of brain pathology can be visualized in the cerebrospinal fluid (CSF) by protein profiling. It is clear that the fiel...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-017-0265-7

    authors： Vanderstichele H,Demeyer L,Janelidze S,Coart E,Stoops E,Mauroo K,Herbst V,François C,Hansson O

    更新日期：2017-06-06 00:00:00

  • Differential effects of chronic immunosuppression on behavioral, epigenetic, and Alzheimer's disease-associated markers in 3xTg-AD mice.

    abstract：BACKGROUND:Circulating autoantibodies and sex-dependent discrepancy in prevalence are unexplained phenomena of Alzheimer's disease (AD). Using the 3xTg-AD mouse model, we reported that adult males show early manifestations of systemic autoimmunity, increased emotional reactivity, enhanced expression of the histone vari...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00745-9

    authors： Kapadia M,Mian MF,Ma D,Hutton CP,Azam A,Narkaj K,Cao C,Brown B,Michalski B,Morgan D,Forsythe P,Zovkic IB,Fahnestock M,Sakic B

    更新日期：2021-01-20 00:00:00

  • Inflammation in the Alzheimer's disease cascade: culprit or innocent bystander?

    abstract：:The strongest known risk factors for late-onset Alzheimer disease (LOAD) remain a positive family history and the APOE epsilon4 allele. van Exel and colleagues used these known risk factors to identify high- and low-risk samples of middle-aged persons in whom they compared levels of inflammatory and vascular risk fact...

    journal_title：Alzheimer's research & therapy

    pub_type： 社论

    doi：10.1186/alzrt29

    authors： Tan ZS,Seshadri S

    更新日期：2010-04-12 00:00:00

  • Analysis of brain region-specific co-expression networks reveals clustering of established and novel genes associated with Alzheimer disease.

    abstract：BACKGROUND:Identifying and understanding the functional role of genetic risk factors for Alzheimer disease (AD) has been complicated by the variability of genetic influences across brain regions and confounding with age-related neurodegeneration. METHODS:A gene co-expression network was constructed using data obtained...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-020-00674-7

    authors： Lancour D,Dupuis J,Mayeux R,Haines JL,Pericak-Vance MA,Schellenberg GC,Crovella M,Farrer LA,Kasif S

    更新日期：2020-09-02 00:00:00

  • Diffusion kurtosis imaging allows the early detection and longitudinal follow-up of amyloid-β-induced pathology.

    abstract：BACKGROUND:Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia in the elderly population. In this study, we used the APP/PS1 transgenic mouse model to explore the feasibility of using diffusion kurtosis imaging (DKI) as a tool for the early detection of microstruct...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-017-0329-8

    authors： Praet J,Manyakov NV,Muchene L,Mai Z,Terzopoulos V,de Backer S,Torremans A,Guns PJ,Van De Casteele T,Bottelbergs A,Van Broeck B,Sijbers J,Smeets D,Shkedy Z,Bijnens L,Pemberton DJ,Schmidt ME,Van der Linden A,Verhoye M

    更新日期：2018-01-09 00:00:00

  • A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans.

    abstract：BACKGROUND:In Alzheimer's disease, beta-amyloid peptides in the brain aggregate into toxic oligomers and plaques, a process which is associated with neuronal degeneration, memory loss, and cognitive decline. One therapeutic strategy is to decrease the production of potentially toxic beta-amyloid species by the use of i...

    journal_title：Alzheimer's research & therapy

    pub_type： 临床试验,杂志文章

    doi：10.1186/s13195-016-0178-x

    authors： Hölttä M,Dean RA,Siemers E,Mawuenyega KG,Sigurdson W,May PC,Holtzman DM,Portelius E,Zetterberg H,Bateman RJ,Blennow K,Gobom J

    更新日期：2016-03-07 00:00:00

  • Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.

    abstract：BACKGROUND:Whether age at onset influences Alzheimer's disease (AD) progression and the effectiveness of cholinesterase inhibitor (ChEI) therapy is not clear. We aimed to compare longitudinal cognitive and global outcomes in ChEI-treated patients with early-onset Alzheimer's disease (EOAD) versus late-onset Alzheimer's...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章,多中心研究

    doi：10.1186/s13195-017-0294-2

    authors： Wattmo C,Wallin ÅK

    更新日期：2017-08-31 00:00:00

  • A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease.

    abstract：INTRODUCTION:There is a great need for quick tests that identify treatment response in Alzheimer's disease (AD) to determine who benefits from the treatment. In this study, A Quick Test of cognitive speed (AQT) was compared with the mini-mental state examination (MMSE) in the evaluation of treatment outcome in AD. MET...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt53

    authors： Palmqvist S,Minthon L,Wattmo C,Londos E,Hansson O

    更新日期：2010-10-15 00:00:00

  • In vivo quantification of neurofibrillary tangles with [18F]MK-6240.

    abstract：BACKGROUND:Imaging agents capable of quantifying the brain's tau aggregates will allow a more precise staging of Alzheimer's disease (AD). The aim of the present study was to examine the in vitro properties as well as the in vivo kinetics, using gold standard methods, of the novel positron emission tomography (PET) tau...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/s13195-018-0402-y

    authors： Pascoal TA,Shin M,Kang MS,Chamoun M,Chartrand D,Mathotaarachchi S,Bennacef I,Therriault J,Ng KP,Hopewell R,Bouhachi R,Hsiao HH,Benedet AL,Soucy JP,Massarweh G,Gauthier S,Rosa-Neto P

    更新日期：2018-07-31 00:00:00

  • Systematic reviews on behavioural and psychological symptoms in the older or demented population.

    abstract：INTRODUCTION:Behavioural and psychological symptoms of dementia (BPS) include depressive symptoms, anxiety, apathy, sleep problems, irritability, psychosis, wandering, elation and agitation, and are common in the non-demented and demented population. METHODS:We have undertaken a systematic review of reviews to give a ...

    journal_title：Alzheimer's research & therapy

    pub_type： 杂志文章

    doi：10.1186/alzrt131

    authors： van der Linde RM,Stephan BC,Savva GM,Dening T,Brayne C

    更新日期：2012-07-11 00:00:00